In this study, microarray data analysis, real-time quantitative PCR and immunohistochemistry were used to detect the expression levels of SSRP1 in colorectal cancer (CRC) tissue and in corresponding normal tissue. The association between structurespecific recognition protein 1 (SSRP1) expression and patient prognosis was examined by Kaplan-Meier analysis. SSRP1 was knocked down and overexpressed in CRC cell lines, and its effects on proliferation, cell cycling, migration, invasion, cellular energy metabolism, apoptosis, chemotherapeutic drug sensitivity and cell phenotype-related molecules were assessed. The growth of xenograft tumours in nude mice was also assessed. MiRNAs that potentially targeted SSRP1 were determined by bioinformatic analysis, Western blotting and luciferase reporter assays. We showed that SSRP1 mRNA levels were significantly increased in CRC tissue. We also confirmed that this upregulation was related to the terminal tumour stage in CRC patients, and high expression levels of SSRP1 predicted shorter disease-free survival and faster relapse. We also found that SSRP1 modulated proliferation, metastasis, cellular energy metabolism and the epithelial-mesenchymal transition in CRC. Furthermore, SSRP1 induced apoptosis and SSRP1 knockdown augmented the sensitivity of CRC cells to 5-fluorouracil and cisplatin. Moreover, we explored the molecular mechanisms accounting for the dysregulation of SSRP1 in CRC and identified
| INTRODUCTION
Colorectal cancer (CRC) is one of the most commonly diagnosed cancers and one of the major causes of cancer mortality worldwide. 1 CRC is often diagnosed at an advanced stage, is accompanied by metastasis, which is negatively correlated with patient survival, and CRC remains incurable. [2] [3] [4] Therefore, the discovery of new diagnostic and prognostic markers and a better understanding of the molecular mechanisms of colorectal tumorigenesis and metastasis are urgently needed.
Structure-specific recognition protein 1 (SSRP1), which is a subunit of the histone chaperone facilitates chromatin transcription (FACT) complex, is involved in almost all chromatin-related processes, including DNA replication, repair and transcription. [5] [6] [7] [8] [9] SSRP1
is not widely expressed in most mature tissues and is detectable in only a very limited number of adult cells. 10 SSRP1 is highly expressed in the early stages of embryonic development, and its expression is reduced gradually in the organs as birth nears and postnatal life begins, which suggests that SSRP1 plays a role in maintaining the undifferentiated cell state. [10] [11] [12] Moreover, SSRP1 is upregulated in various tumours, such as breast cancer and ovarian cancer, and is associated with a worse prognosis. [13] [14] [15] RNA interference (RNAi) knocks down SSRP1, inhibits tumour transformation and impairs tumour cell viability, but nontumour cells can tolerate this knockdown well. 16 An inhibitor of SSRP1, CBL0137, causes cell death via blocking SSRP1-dependent p53 activation as well as the downregulation of a subset of nuclear factor-kappaB (NF-κB)-dependent genes; CBL0137 has been developed for human use and is currently being investigated in cancer clinical trials. 17, 18 These results imply that SSRP1 is a potential target in cancer therapy. However, the function, mechanism and clinical value of SSRP1 in CRC remain obscure. In addition, although SSRP1 has been shown to induce many types of human cancers, previous studies have concentrated only on its role in stimulating proliferation by promoting cell cycle progression; its functions in metastasis and chemoresistance have rarely been investigated. Another problem to address is the mechanism underlying high SSRP1 expression in cancer tissue. MicroRNAs (miRNAs) are small noncoding RNA molecules that are highly conserved and can induce mRNA cleavage or repress translation by targeting the 3'UTR of corresponding mRNAs. [19] [20] [21] Recently, an increasing number of studies have reported that miRNAs can regulate various cellular processes in cancer, such as proliferation, apoptosis, metastasis and chemoresistance. 20 In this study, we have been suggested that the abnormal expression of SSRP1 in CRC is partly due to the upstream dysregulation of miRNAs.
In this study, we provided the first data regarding the expression levels of SSRP1 and its clinical significance in human CRC. We found that SSRP1 is up-regulated in CRC and significantly affects not only proliferation but also metastasis and chemosensitivity in CRC. We also showed the negative regulation of SSRP1 levels by microRNA-28-5p (miR-28-5p). In conclusion, we found that SSRP1 is an important oncogene in CRC, and the pathogenic up-regulation of SSRP1 is partially attributed to the down-regulation of miR-28-5p. 
| MATERIALS AND METHODS

| Patients and immunohistochemistry
| 3119 SSRP1 (15696-1-AP), E-cadherin (20874-1-AP), N-cadherin (22018-1- AP), ZO-1 (21773-1-AP), ZEB1 (21544-1-AP), ZEB2 (14026-1-AP),
| Western blotting
Colorectal cancer proteins were separated by SDS polyacrylamide gel electrophoresis. Proteins were transferred onto a polyvinylidene fluoride membrane and incubated for 60 minutes in TBST (0.05%
Tween-20 in phosphate-buffered saline) with 5% dried skim milk at room temperature. Immunoblot analysis was performed using the appropriate primary antibody at 4°C for 12 hours. After being washed three times, the membranes were incubated with a horseradish peroxidase conjugated secondary antibody for 60 minutes.
Immunoreactive bands were visualized with an enhanced chemiluminescent detection kit (Beyotime Biotechnology Co., Ltd).
| Quantitative real-time PCR
Total RNA was isolated from cell lines and human tissues using an RNA iso- 
| Metabolic analyses
The oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were measured with an XF Extracellular Flux Analyser (Seahorse Bioscience). We used a protocol previously described. 22 The data were analysed using Seahorse XF software. OCR and ECAR measurements were normalized to either the final cell number or the protein concentration.
| Cell cycle analysis
One million cells were used for the cell cycle analyses. The cells were fixed in cold methanol for at least 2 hours and then incubated with a propidium iodide (PI)/RNase A solution. The cell cycle distribution was assessed with a FACSCalibur system (Becton-Dickinson, NJ, USA). Modfit 2.0 software was used to detect the percentage of cells in different phases. 
| Apoptosis analysis
| Migration and invasion assays
In vitro tumour cell motility was measured using transwell migration 
| In vivo tumorigenicity assay
Male BALB/C nude mice that were 5 weeks old and weighed 20- 
| Luciferase assay
We obtained pMIR-REPORT luciferase plasmids (Obio Technology 
| Statistical analysis
Each experiment was performed at least three times. Survival analyses were statistically analysed by the log-rank test. The unpaired Student's t test and one-way ANOVA were used to analyse the differences between two variables and multiple variables, respectively.
A significant difference was defined as P < 0.05.
| RESULTS
| SSRP1 expression is up-regulated in CRC
We first analysed SSRP1 mRNA expression in CRC patients from two independent GEO datasets, GSE32323 and GSE4107. The two datasets included paired CRC tumour and adjacent noncancerous tissue mRNA information. As shown in Figure 1A , SSRP1 mRNA levels were significantly higher in human colorectal tumour tissue than those in adjacent normal colorectal tissue.
To (Table S1 ; 60 cases of colon cancer and 20 cases of rectal carcinoma) and their paired normal tissue. SSRP1 was located in the cytoplasm and nucleus ( Figure 1D ,E), which was in accordance with the results of previous reports. 17, 23 As shown, SSRP1 was up-regulated in the majority (85%, 68/80) of the CRC specimens ( Figure 1F ).
In conclusion, these data clearly indicated that SSRP1 was up-regulated in CRC at both the mRNA and protein levels, which hinted at the importance of SSRP1 in the pathogenesis of CRC.
| SSRP1 expression levels are correlated with disease progression and shortened patient survival
To confirm the correlation between SSRP1 expression levels and clinicopathological factors in CRC, the clinical information for GSE14333 was downloaded and statistically analysed. The pooled samples in the dataset were then divided into two groups based on the SSRP1 expression level in the tumour tissue, and the chi-squared test was applied. As shown in Table 1 , higher SSRP1 expression level was closely related to the Dukes stage (P = 0.003). The results suggested that high SSRP1 expression was associated with rapid carcinoma spread. Importantly, the results showed that CRC patients with tumours with high SSRP1 expression levels had markedly shorter DFS and RFS than those with tumours with low SSRP1 expression ( Figure S1A ,B) (P = 0.0025 and P = 0.019, respectively).
These findings strongly suggest that SSRP1 may be a new prognostic factor for CRC.
| SSRP1 modulates CRC cell proliferation in vitro and in vivo
To verify the biological role of SSRP1 in CRC cell proliferation, we depleted SSRP1 in HCT116 and SW480 cells using three siRNAs.
After transfecting the three siRNAs into CRC cells, we used Western blot analysis to measure the SSRP1 protein levels. To verify the effect of SSRP1 on CRC progression in vivo, we performed xenograft tumour assays using HCT116 cells stably transfected with SSRP1-overexpression lentiviruses or control lentiviruses.
We found that the lentiviral expression of SSRP1 resulted in accelerated xenograft tumour growth ( Figure 2B,C) . These data collectively demonstrate that SSRP1 expression is closely related to the proliferation of CRC cells.
Cell proliferation depends largely on cell cycle progression. Hence, the impact of SSRP1 knockdown on the cell cycle process was also assessed by flow cytometry. After treatment with si-SSRP1 or control siRNA for 48 hours, the cells were collected and stained with PI.
SSRP1 knockdown resulted in an obvious accumulation of cells in the G0/G1 phase and a considerable decrease in the proportion of cells in the S/G2/M phases in HCT116 ( Figure 2D ) and SW480 cells (Figure S3B) ; in contrast, the overexpression of SSRP1 promoted cell cycle progression in HCT116 cells ( Figure 2E ). These data suggest that WU ET AL.
| 3121 SSRP1 modulates the cell cycle. We proceeded to determine the expression levels of p53, which is a key cell cycle regulator. 24 As shown in Figure 2F , we determined p53 expression levels after SSRP1 knockdown and found that SSRP1 knockdown led to an increase in p53 protein levels. We further examined several p53 downstream cell-cycle-related molecules and found that p21 and p27 were up-regulated following SSRP1 knockdown in HCT116 cells. The expression levels of cyclin D1 and 14-3-3, which is a cyclin negatively regulated by p21, were reduced in SSRP1 knockdown cells. Moreover, the overexpression of SSRP1 had the opposite effect.
These results showed SSRP1 regulates p53 and its related downstream molecules. The regulation of the p53 pathway by SSRP1 might be the underlying mechanism of SSRP1-mediated cell cycle progression in CRC cells.
| SSRP1 modulates cell phenotypes and associated molecules in CRC
The role of SSRP1 has not been well characterized in cancer metastasis. We determined whether SSRP1 is a key molecule that has an impact on cell migration and invasion by transwell assay. As shown, knocking down SSRP1 inhibited the migration and invasion rates of SW480 and HCT116 cells ( Figure 3A,B) ; in contrast, the forced expression of SSRP1 had the opposite effect on HCT116 cells (Figure 3C) . These results demonstrated that the expression level of SSRP1 is positively related to cell migration and invasion. It is well known that VEGF and MMP9 are critical proteins for cancer cell invasion and metastasis and that the autocrine secretion of these cytokines by cancer cells critically influences cancer cell behaviours F I G U R E 1 SSRP1 expression is upregulated in CRC. A, SSRP1 expression levels in CRC tissue and normal tissue in two independent cohorts (GSE32323 and GSE4107). B, SSRP1 mRNA expression levels in 10 paired tissue tumour samples and normal tissue samples. C, SSRP1 protein expression levels in five CRC cell lines and the normal colon NCM460 cell line. D and E, Representative photographs of IHC staining for SSRP1 in normal and CRC tissue. F, SSRP1 expression was up-regulated in 85% of CRC patients according to IHC. *P < 0.05, **P < 0.01, and ***P < 0.001. IHC: immunohistochemical staining such as invasion. 25 When SSRP1 was knocked down in HCT116 cells, MMP9 and VEGF were down-regulated ( Figure 3D ), and the opposite regulation was seen in SSRP1-overexpressing cells.
The epithelial-mesenchymal transition (EMT) plays an important role in cancer progression and metastasis. 26 Given that SSRP1 promotes the migration and invasion of CRC cell lines, we next tested whether SSRP1 affects the EMT process in CRC. Consistent with our hypothesis, the protein expression levels of the epithelial markers ZO-1 and E-cadherin were obviously decreased in stable SSRP1-overexpressing HCT116 cells; in contrast, the expression levels of the mesenchymal markers Snail, Slug, ZEB1, ZEB2, N-cadherin and Twist were dramatically increased ( Figure 3D ). Corresponding results were obtained with SSRP1-knockdown HCT116 cells ( Figure 3D ).
Collectively, our results show that SSRP1 contributes to the promotion of EMT in CRC cells, which at least partly explains why SSRP1 overexpression promotes metastasis and invasion in CRC cells.
Many oncogenes or tumour suppressor genes are deregulated during tumorigenesis, which leads to the abnormal cellular bioenergetics that give cancer cells a growth advantage. Increases in glycolysis and mitochondrial biogenesis are the most prominent metabolic alterations in cancer. 22 The ECAR is an indicator of glycolysis, and the OCR is an indicator of mitochondrial respiration. Hence, the impacts of SSRP1 on ECAR and OCR were also assessed. SSRP1-overexpressing CRC cells showed a higher rate of glycolysis and a higher mitochondrial respiratory ratio than the mock-treated and control cells according to the ECAR and OCR, while SSRP1 knockdown had the inverse effect ( Figure S4A,B) .
These data show that SSRP1 promotes malignant progression by promoting CRC cell motility and increasing glycolysis and aerobic oxidation.
| SSRP1 modulates the sensitivity of CRC cells to chemotherapeutic drugs
After exploring the function of SSRP1 in CRC cell growth and metastasis, we attempted to determine whether SSRP1 could be used for clinical CRC treatment. Chemotherapy is an important strategy for the treatment of CRC. However, primary and secondary drug resistance is a major challenge in basic and clinical research, which greatly reduces the antitumour efficacy of therapy in many cases. 27 We first deter- 
| Identification of SSRP1 as a new target for miR-28-5p
MiRNAs play an important role in gene expression regulation. It would be interesting to confirm whether a specific miRNA could regulate SSRP1 expression in CRC. Potential miRNAs that target the 3UTR of SSRP1 were predicted, and their target sites were analysed by TargetScan, miRanda and miRwalk. To reduce false positives, candidates were considered only if they were predicted by all three methods. One candidate identified by this approach was miR-28-5p, which has one site complementary to the 3UTR of SSRP1 (Figure 5A ). It has been confirmed that miR-28-5p is down-regulated in CRC; we also verified this by analysing the GEO datasets ( Figure 5B ). Furthermore, the overexpression of miR-28-5p inhibited CRC cell proliferation, migration, and invasion. 29 Importantly, Kaplan-Meier survival analysis suggested that CRC patients with tumours with low miR-28-5p expression levels had observably shorter DFS times than those with tumours with high miR-28-5p expression ( Figure 5C ) (P = 0.015). Therefore, we proposed that the overexpression of SSRP1 was partly attributed to the down-regulation of miR-28-5p.
After transfection with miR-28-5p, we observed that SSRP1 protein levels decreased in SW480 and HCT116 cells ( Figure 5D ). We found that miR-28-5p could suppress the reporter gene activity of SSRP1 in HEK293T cells; in addition, the suppression was weaker when the mutation plasmid (MT plasmid) was used ( Figure 5E ). These data indicated that SSRP1 was a direct target of miR-28-5p. A negative correlation was also observed between miR-28-5p and SSRP1
expression levels in CRC samples ( Figure 5F ; P < 0.0001, R = −0.731). These data support the idea that SSRP1 expression is negatively regulated by miR-28-5p in CRC.
| DISCUSSION
Our study shows that SSRP1 promotes CRC progression, which agrees with previous studies in other types of cancers, such as nonsmall cell lung cancer, 30 breast cancer 13, 31 and hepatic carcinoma (HCC). 23 Significantly shortened survival is observed in patients with high SSRP1 expression compared with patients with low SSRP1 expression. Our data suggest that SSRP1 knockdown inhibited the cell cycle and promoted apoptosis in CRC cells in vitro, which may result in slower cancer cell proliferation in vivo. However, the underlying mechanism is still unclear, and several possible explanations are put forward here.
F I G U R E 2 SSRP1 modulates CRC cell proliferation and the cell cycle in HCT116 cells. A, SSRP1 knockdown or overexpression reduced or accelerated the proliferation rate of cells, respectively. B, Representative data show that the overexpression of SSRP1 significantly promoted tumour growth in a nude mouse xenograft model (n = 6). C, Tumours were dissected, and tumours from the two groups are shown. D, The effects of SSRP1 knockdown on the cell cycle were determined. The percentages of cells in the G1, S and G2/M phases of the cell cycle are presented. The bars represent the mean values of six independent tests (mean ± SD). E, The effects of SSRP1 overexpression on the cell cycle were determined. F, Cell cycle-related molecules were screened by Western blot analysis, and SSRP1 expression levels altered the expression of cell-cycle-related proteins in HCT116 cells. *P < 0.05, and **P < 0.01. p21: cyclin-dependent kinase inhibitor 1A; p27: Cyclin-dependent kinase inhibitor 1B; 14-3-3: YWHAS, epithelial cell marker protein 1
First, a hallmark of cancer cells is that they maintain proliferative ability, which can be achieved by inactivating tumour-suppressor genes and dysregulating tumour-associated transcription factors. P53 is a widely known tumour suppressor. 32 The deregulation of the transcription factor NF-κB is a common event in many types of cancers that are susceptible to tumour initiation and progression via the expression of proproliferative/antiapoptotic genes. 33 It has been reported that the NF-κB and p53 pathways can be modified by the FACT complex. 13, 30 Curaxins can effectively bind the heterodimeric protein complex FACT, and the sequestration of FACT leads to the regulation of various pathways (p53 activation and NF-κB inhibition), resulting in tumour cell death without DNA damage. 17, 18, 34 Hence, the activation of the NF-κB pathway and the suppression of the p53 pathway could be considered a mechanism underlying SSRP1 function in CRC tumorigenesis.
P53 expression is associated with cell cycle arrest. 24 Moreover, cell cycle proteins, such as p21 and p27, are the signalling factors downstream of p53, which can be regulated by p53. In addition, the expression levels of cyclin D1 and 14-3-3 can be negatively regulated by p21. The p27 amino-terminal region has 44% similarity with p21, which prevents cells moving from the G0/G1 to S phase transition. 35 In this paper, we measured the expression of p53 and its In addition, cancer cells maintain proliferative signalling, which is accompanied by enhanced DNA replication. 36 SSRP1 is a key regulator maintaining DNA replication in the normal cell process. 37 SSRP1
knockdown inhibited cell growth due to the inhibition of duplication fork progression. 38 Furthermore, it has been reported that SSRP1 is involved in canonical Wnt/β-catenin-mediated signalling pathways.
11
The activation of the Wnt/β-catenin signalling pathway also plays a key role in the formation of CRC; mutations in the negative regulatory components of APC occur in more than 90% of colorectal tumours. 39 We have been suggested that the high expression levels of SSRP1 regulate the Wnt/β-catenin pathways in CRC. In the present study, when SSRP1 was knocked down or overexpressed, the signalling molecules downstream of the Wnt/β-catenin pathway and those associated with EMT changed significantly. Therefore, we speculated that SSRP1 may promote the malignant biological behaviour of CRC cells by promoting EMT via the Wnt/β-catenin pathway. Lastly, the expression levels of MYC and FACT are obviously higher in malignant tissue than those in normal tissue. 10, 15, 40 The MYC oncogene is believed to be involved in more than half of F I G U R E 3 SSRP1 modulates cell motility and phenotype-related molecules in CRC. A, Cell migration was assessed by transwell migration assay in SSRP1 knockdown cells. B, Cell invasion was assessed by transwell invasion assay in SSRP1 knockdown cells. C and D, Cell migration and invasion were assessed by transwell assay in SSRP1 overexpressing cells. E, Phenotype-related molecules were screened by Western blot analysis human tumours. 3 There is an interaction between MYC and FACT that causes MYC to directly drive the transcription of SUPT16H and SSRP1, and FACT then positively regulates MYC expression and protein stability in turn. 41 Animal models with conditional gene knockout of SSRP1 or Spt16 have revealed the specific functions of FACT in neuroblastoma development and, by association, in MYC-driven tumorigenesis. 41 These reports suggest several possible mechanisms by which SSRP1 may regulate malignant cell progression in CRC.
In our work, we confirmed that SSRP1 modulates not only proliferation but also motility, migration, invasion and chemosensitivity. In CRC, metastasis is the most fatal event during disease progression; it accounts for approximately 90% of patient deaths. 42 Metastasis is inversely related to the survival of the patient and critically limits successful therapy. 43 Metastasis formation is a major obstacle in CRC therapy. Therefore, the identification of high-risk patients with metastasis formation and the early diagnosis and molecular characterization of primary tumours are vital steps to determine prognostic and therapeutic markers. 44 Our results suggest that SSRP1 is an important target for impeding metastasis in CRC. Chemotherapy is one of the most effective methods of treatment. However, aberrant cell signalling activation and exceptional changes in some oncogenes often lead to uncontrolled drug resistance, recurrence and metastasis. 45 and HCC. 51 Increasing evidence indicates that miR-28-5p negatively regulates a number of well-characterized oncogenic proteins, such as CCND1, HOXB3, 29 IL-34, FAK, ERK1/2 51 and insulin-like growth factor 1. 52 In this study, miR-28-5p expression was down-regulated in CRC samples compared with that in normal colon samples, and the down-regulation of miR-28-5p forecasted a poor prognosis for CRC patients, suggesting that this miRNA plays a tumour-suppressive role.
Most cells in human tissue do not express SSRP1 at the protein level, but SSRP1 is expressed at high levels in undifferentiated or cancerous tissues; however, the mechanisms of SSRP1 up-regulation
have not yet been determined in cancer. Our work showed that SSRP1 is a new target of miR-28-5p and that there is a negative relationship between miR-28-5p and SSRP1 expression. Taken together, these results reveal a novel regulatory pathway employing miR-28-5p and SSRP1 to fine-tune the balance of CRC.
In summary, our study has shown the biological and clinical significance of SSRP1 in CRC. Our study demonstrated that SSRP1 expression is observably up-regulated in CRC tissue and is correlated with the Dukes stage of the tumour. SSRP1 is a newly identified target of miR-28-5p; this finding partially explains the abnormally high expression of SSRP1 in cancers. Our evidence provides novel clues that may aid CRC diagnosis and treatment in the future. However, it will be necessary to further explore the molecular mechanisms of SSRP1 in promoting proliferation, metastasis and drug resistance in depth.
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